雅培Abbott Laboratories （ABT）2025年第二季度业绩报告（英文版）（14页）.pdf

1、ABBOTT REPORTS SECOND-QUARTER 2025 RESULTSSecond-quarter reported sales growth of 7.4 percent;organic sales growth of 6.9 percent or 7.5 percentexcluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of$1.01;adjusted diluted EPS of$1.26Reported gross margin of 52.7 percent of sales;

2、adjusted gross margin of 57.0 percent,which reflects a100 basis point increaseReported operating margin of 18.4 percent of sales;adjusted operating margin of 22.9 percent,whichreflects a 100 basis point increaseABBOTT PARK,Ill.,July 17,2025/PRNewswire/-Abbott(NYSE:ABT)today announced financial resul

3、ts for the second quarterended June 30,2025.Second-quarter sales increased 7.4 percent on a reported basis,6.9 percent on an organic basis,or 7.5 percent whenexcluding COVID-19 testing-related sales1.Second-quarter GAAP diluted EPS of$1.01 and adjusted diluted EPS of$1.26,which excludes specified it

4、ems andreflects double-digit growth compared to the prior year.First-half sales increased 5.7 percent on a reported basis,6.9 percent on an organic basis,or 7.9 percent whenexcluding COVID-19 testing-related sales2.Abbott projects full-year 2025 organic sales growth,excluding COVID-19 testing-relate

5、d sales,to be 7.5%to 8.0%,or6.0%to 7.0%when including COVID-19 testing-related sales.Abbott projects full-year 2025 adjusted diluted EPS of$5.10 to$5.20,which reflects double-digit growth at the midpoint.In April,Abbott completed enrollment ahead of schedule in its FlexPulse U.S.IDE trial,which is d

6、esigned to evaluate theTactiFlex Duo Pulsed Field Ablation(PFA)System for treating patients with heart rhythm disorders such as atrialfibrillation(AFib).In April,Abbott announced late-breaking data from the AVEIR Conduction System Pacing(CSP)clinical feasibility study.This study was the worlds first